We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KERX
301
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-167,999
Closed -$2.86M
KERX
302
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-5,238
Closed -$8.93M
AEGR
303
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-34,420
Closed -$1.28M
DYAX
304
CALL
DELISTED
DYAX CORPORATION
DYAX
– –
-163
Closed -$146K
DYAX
305
DELISTED
DYAX CORPORATION
DYAX
– –
-230,000
Closed -$2.06M
GEVA
306
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-13,538
Closed -$1.15M
PCYC
307
CALL
DELISTED
PHARMACYCLICS INC
PCYC
– –
-1,500
Closed -$15M
AVNR
308
PUT
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-3,750
Closed -$1.38M
IDIX
309
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
– –
-1,302
Closed -$785K
FURX
310
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-7,180
Closed -$704K
BDSI
311
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-3,952
Closed -$3.33M
VVUS
312
DELISTED
Vivus Inc
VVUS
– –
-2,203
Closed -$113K
VVUS
313
PUT
DELISTED
Vivus Inc
VVUS
– –
-19
Closed -$112K
CELG
314
DELISTED
Celgene Corp
CELG
– –
-38,998
Closed -$2.97M
MDVN
315
CALL
DELISTED
MEDIVATION, INC.
MDVN
– –
-860
Closed -$2.77M
9 10 11 12
13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.